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Retrospective review of patients treated with argatroban for 
heparin induced thrombocytopenia 
Jessica Justiz, Pharm. D., Jessica Greenwood, Pharm. D., Heidi Clarke, Pharm. D., BCCCP, Radhan B. Gopalani, Pharm. D., BCPS
Baptist Hospital of Miami, Department of Pharmacy; Miami, FL
• Heparin induced thrombocytopenia (HIT) is potentially a 
life-threatening complication caused by an immunological 
response to heparin exposure characterized by 
thrombocytopenia with a paradoxical increase in the 
incidence of thrombosis.1,2,3
• The American Society of Hematology recommends the 
discontinuation of heparin, administration of a non-heparin 
anticoagulant, and HIT confirmation with a serologic assay 
upon suspicion of HIT.4
• A challenge remains with the over-diagnosis and treatment 
of HIT based solely on laboratory results (i.e., PF4 ELISA 
assay results), rather than with corresponding risk factor 
assessments (i.e., 4T score and PF4 ELISA assay).2
• Inappropriate use of argatroban may potentiate bleeding 
complications.5
The purpose of this study is to review the utilization of 
argatroban in patients with a suspected diagnosis of HIT and 
evaluate their clinical outcomes. 
• Retrospective observational chart review of patients 
admitted to Baptist Hospital of Miami from January 1, 2018 
to July 31, 2018 treated with argatroban
• Inclusion Criteria:
• Patients 18 years of age and older
• Positive PF4 test result [optical density (OD) ≥ 0.4] 
• Received treatment with argatroban
• Exclusion Criteria:
• History of HIT prior to admission 
• Argatroban for extracorporeal circuit patency of 
continuous renal replacement therapy (CRRT) in 
critically-ill patients with HIT
• Argatroban for catheter directed thrombolysis
• Primary Outcome: Stratification of patients into low index of 
suspicion (group A) or high index of suspicion (group B) as 
follows :
• Group A: 4T score <4 
• Group B: 4T score ≥4 
• Secondary Outcomes: Percent reduction in platelets, 
number of SRA test ordered and SRA results, incidence of 
new thromboembolic events, clinically relevant bleeds, and 
deaths
• Fisher’s exact test for discrete data and t-test of unequal 
variance for continuous data was utilized 
All authors of this presentation have nothing to disclose concerning possible financial or personal relationships with commercial entities 
that may have direct or indirect interest in the subject matter of this presentation.
1. Cuker A, Cines DB. How I treat heparin-induced thrombocytopenia. Blood. 2012;119(10):2209-2218.
2. Lee GM, Arepally GM. Heparin-induced thrombocytopenia. American Society of Hematology. 2013:668-674.
3. Sakr Y. Heparin-induced thrombocytopenia in the ICU: an overview. Critical Care. 2011;15(2):211. 
4. Berry C, Tcherniantchouk O, Ley EJ, et al. Overdiagnosis of Heparin-Induced Thrombocytopenia in Surgical ICU Patients. Journal of the American 
College of Surgeons. 2011;213(1):10-17. 
5. Marler J, Unzaga J, Stelts S, Oliphant CS. Consequences of treating false positive heparin-induced thrombocytopenia. Journal of Thrombosis and 
Thrombolysis. 2015;40(4):512-514. 
• A sample size of 194 would have been required to detect a significant difference 
with 80% power 
• Prior heparin exposure could not be confirmed 
• Observed rates of thrombosis and clinically relevant bleeds were evaluated for 
current hospital admission only
CONCLUSIONS
• A high index of suspicion is recommended for diagnosing HIT 
• Disease states and medication can cause thrombocytopenia 
• False positive PF4 can result from  antiphospholipid syndrome and systemic 
lupus erythematosus
• Pretest probability assessment with 4T score calculations should be taken into 
consideration prior to ordering ELISA PF4/heparin antibodies tests
• Prospective studies will be required to test the clinical utility and safety of a 








• 65% of patients with a low 4T score received treatment with argatroban
• 69.2% of patients in Group B experienced a new thromboembolic event versus 
8.3% for those in group A
• A higher proportion (54%) of patients in Group B had ≥ 50% reduction in PLTs
Secondary Outcome Measures 





Mean % reduction in PLTs 5% 33.7%
Mean # of days between PLT reduction 5 8
Functional Serotonin Release Assay (SRA)
SRAs ordered 5 4
Positive SRAs 0 1
Adverse Events 
Clinically relevant bleeds 3 (12.5%) 0
Deaths* 2 (8.3%) 0
RESULTS
Baseline Demographics n=37
Mean Age (years) 65
Mean SCr (mg/mL) 2.84
Mean CrCl (mL/min) 52
Mean AST (units/L) 46
Mean ALT (units/L) 33
Heparin Product Exposure
Group A Group B
Heparin IV 8 (33%) 7 (54%)
Heparin SubQ 8 (33%) 4 (31%)
Heparin via dialysis 3 (13%) 2 (15%)







Average 4T Score 1.3 4.6 <0.000002
PF4 mean OD 1.005 1.371 0.299
PF4 OD ≥ 2 1 (4%) 4 (31%) 0.423
New thromboembolic events 2 (8.3%) 9 (69.2%) 0.0002
*Non-argatroban related deaths
n= 13
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